{"schema_version":"1.0","type":"article","title":"減重17.7%，恆瑞還要過全球試驗","url":"https://drugnews.com.tw/articles/2026-11-20-hengrui-ribupatide-weight-loss.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-20-hengrui-ribupatide-weight-loss.md","lang":"zh-Hant","date":"2026-11-20","publish_at":"2026-11-20T08:00:00+08:00","updated_at":"2026-11-20","category":"商業分析系列","topic":"科學介紹","tags":["減重","ribupatide","恆瑞","Kailera","GLP-1"],"summary":"Ribupatide中國三期48週平均減重17.7%，安慰劑1.4%。四試驗的週數與人群不同；三計畫60.35億美元名目上限中，已付首款與技轉費1.10億美元。","key_points":["Ribupatide有中國三期安慰劑對照證據，全球位置待全球試驗；授權上限分三計畫與條件。","療效、胃腸事件與停藥率各自閱讀。","名目上限與已核付款分列。"],"facts":[{"claim":"GEMINI-1 randomized enrollment","value":567,"unit":"participants","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"GEMINI-1 treatment duration","value":48,"unit":"weeks","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"GEMINI-1 baseline mean weight","value":93,"unit":"kg","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"GEMINI-1 baseline mean BMI","value":33.3,"unit":"kg/m2","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"Weight change 2/4/6mg","value":[-10.7,-16.4,-17.7],"unit":"percent; treatment policy","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"Placebo weight change","value":-1.4,"unit":"percent; treatment policy","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"6mg minus placebo weight change","value":-16.3,"unit":"percentage points","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"6mg at least 15% weight reduction","value":63.8,"unit":"percent of participants","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"6mg at least 10% weight reduction","value":75.4,"unit":"percent of participants","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"GI events 2/4/6mg/placebo","value":[47.9,58.2,63.1,23.1],"unit":"percent","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"AE permanent discontinuation 2/4/6mg/placebo","value":[0.7,0.7,1.4,0],"unit":"percent","as_of":"2026-11-15","source":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"claim":"Ribupatide all-cause treatment discontinuation","value":9.4,"unit":"percent; 40/424","as_of":"2025-11","source":"https://www.kailera.com/wp-content/uploads/2025/11/Hengrui_ObesityWeek-2025_HRS9531_Phase_3_Clinical_Trial_Results.pdf"},{"claim":"License upfront payment","value":100,"unit":"USD million","as_of":"2026-11-04","source":"https://investors.kailera.com/static-files/c21ffedd-0e44-4475-9653-057728910880"},{"claim":"Technology-transfer payment","value":10,"unit":"USD million","as_of":"2026-11-04","source":"https://investors.kailera.com/static-files/c21ffedd-0e44-4475-9653-057728910880"},{"claim":"Paid upfront plus technology transfer","value":110,"unit":"USD million","as_of":"2026-11-04","source":"https://investors.kailera.com/static-files/c21ffedd-0e44-4475-9653-057728910880"},{"claim":"Clinical/regulatory milestone ceiling","value":200,"unit":"USD million","as_of":"2026-03-27","source":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm"},{"claim":"Commercial milestone ceiling","value":5725,"unit":"USD million","as_of":"2026-03-27","source":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm"},{"claim":"Nominal three-program ceiling","value":6035,"unit":"USD million","as_of":"2026-03-27","source":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm"},{"claim":"Historical equity at licensing","value":19.9,"unit":"percent; fully diluted at licensing","as_of":"2026-03-27","source":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm"},{"claim":"KaiNETIC readout company forecast","value":"mid-2028","unit":"forecast, not completed","as_of":"2026-11-04","source":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526447232/ck0002096997-ex99_1.htm"}],"sections":["01｜恆瑞選擇雙受體路線","02｜四個試驗各有自己的時間與病人","03｜胃腸不適與停藥分開讀","04｜條件款與台灣權利分開看","參考資料"],"references":[{"title":"Once-Weekly Ribupatide: GEMINI-1","source":"JAMA","date":"2026-11-15","url":"https://jamanetwork.com/journals/jama/fullarticle/2856795"},{"title":"SURMOUNT-1 results","source":"Eli Lilly","date":"2022-06-04","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine"},{"title":"Introduction to STEP program","source":"Novo Nordisk","date":"","url":"https://www.scientific-exchange.com/content/dam/medical/scientific-exchange/ta/obesity/pharmacotherapies/resource-documents/intro-to-step-program-phase-3-chronic-weight-mgmt-studies.pdf"},{"title":"HRS9531 Phase 3 Clinical Trial Results","source":"Hengrui / Kailera","date":"2025-11","url":"https://www.kailera.com/wp-content/uploads/2025/11/Hengrui_ObesityWeek-2025_HRS9531_Phase_3_Clinical_Trial_Results.pdf"},{"title":"Mazdutide in Chinese Adults with Overweight or Obesity","source":"NEJM","date":"2025-05-25","url":"https://mediacenteratypon.nejmgroup-production.org/NEJMoa2411528.pdf"},{"title":"Third Quarter 2026 Results and Business Updates","source":"Kailera / SEC","date":"2026-11-04","url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526447232/ck0002096997-ex99_1.htm"},{"title":"Form 10-Q, note 12","source":"Kailera","date":"2026-11-04","url":"https://investors.kailera.com/static-files/c21ffedd-0e44-4475-9653-057728910880"},{"title":"Form S-1: Hengrui agreement","source":"Kailera / SEC","date":"2026-03-27","url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm"},{"title":"中國肥胖適應症上市申請受理公告","source":"Hengrui / HKEX","date":"2025-09-01","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0901/2025090102522_c.pdf"},{"title":"GEMINI-1 trial registration","source":"ClinicalTrials.gov","date":"","url":"https://clinicaltrials.gov/study/NCT06396429"}],"images":[{"alt":"圖1｜Ribupatide雙受體機制","url":"https://drugnews.com.tw/assets/articles/hengrui-ribupatide-weight-loss/figure-01.png"},{"alt":"圖2｜同一試驗的48週體重變化","url":"https://drugnews.com.tw/assets/articles/hengrui-ribupatide-weight-loss/figure-02.png"},{"alt":"圖3｜四個試驗的不同條件","url":"https://drugnews.com.tw/assets/articles/hengrui-ribupatide-weight-loss/figure-03.png"},{"alt":"圖4｜已付現金與未來條件款","url":"https://drugnews.com.tw/assets/articles/hengrui-ribupatide-weight-loss/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/hengrui-ribupatide-weight-loss/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-20）。減重17.7%，恆瑞還要過全球試驗。https://drugnews.com.tw/articles/2026-11-20-hengrui-ribupatide-weight-loss.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「Ribupatide有中國三期安慰劑對照證據，全球位置待全球試驗」有哪些關鍵變化？","a":"Ribupatide有中國三期安慰劑對照證據，全球位置待全球試驗；授權上限分三計畫與條件。"},{"q":"「療效、胃腸事件與停藥率各自閱讀」有哪些關鍵變化？","a":"療效、胃腸事件與停藥率各自閱讀。"},{"q":"「名目上限與已核付款分列」有哪些關鍵變化？","a":"名目上限與已核付款分列。"}]}